top of page
Companies in the News
Grain Craft & Indigo Announce Consumer-Driven Supply Agreement for One Million Bushels of Identi
• Indigo to provide Grain Craft with wheat that is sustainably produced, identity preserved, and meets enhanced milling quality...
Dec 13, 2017
Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-
Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN...
Dec 11, 2017
Farming startup Indigo raises $203 million with help from Dubai fund
SAN FRANCISCO (Reuters) - Farming technology startup Indigo has raised more than $200 million from investors to fund its efforts to...
Dec 6, 2017
Indigo Corn™ Demonstrates Significant Yield Gains on Farms Experiencing Severe Water Stress
- Indigo Corn demonstrates a 30+ bushel per acre yield increase on farms under severe water stress - Indigo announces 47 cent per bushel...
Nov 21, 2017
eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunologica
SAN DIEGO, November 10, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for...
Nov 10, 2017
Millendo Therapeutics Announces Positive Topline Phase 2 Results of ATR-101 in Classic Congenital Ad
ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel...
Nov 8, 2017
Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Nove
VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Oct 19, 2017
Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious
-- Expands technology and global footprint with acquisition of Humabs BioMed SA -- Accesses clinical and preclinical stage assets from...
Oct 18, 2017
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of EFT508 and Avelumab in Micros
Study conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics,...
Oct 4, 2017
bottom of page